Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2008
Published online before print June 19, 2008, doi: 10.1161/CIRCRESAHA.108.177386
A more recent version of this article appeared on July 18, 2008
This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
103/2/e15    most recent
CIRCRESAHA.108.177386v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Caporali, A.
Right arrow Articles by Emanueli, C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Caporali, A.
Right arrow Articles by Emanueli, C.
Right arrowPubmed/NCBI databases
*Gene*GEO DataSet
*GEO Profiles*HomoloGene
*Nucleotide*Protein
*UniGene
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*NITRIC OXIDE
*STREPTOZOTOCIN
Related Collections
Right arrow Type 1 diabetes
Right arrow Angiogenesis
Right arrow Apoptosis
Right arrow Cell biology/structural biology
Right arrow Cell signalling/signal transduction

Submitted on April 11, 2008
Revised on June 2, 2008
Accepted on June 11, 2008

Neurotrophin p75 Receptor (p75NTR) Promotes Endothelial Cell Apoptosis and Inhibits Angiogenesis. Implications for Diabetes-Induced Impaired Neovascularization in Ischemic Limb Muscles

Andrea Caporali ; Elisabetta Pani ; Anton J.G. Horrevoets ; Nicolle Kraenkel ; Atsuhiko Oikawa ; Graciela B. Sala-Newby ; Marco Meloni ; Brunella Cristofaro ; Gallia Graiani ; Aurelie S. Leroyer ; Chantal M. Boulanger ; Gaia Spinetti ; Sung Ok Yoon ; Paolo Madeddu ; and Costanza Emanueli *

From the Experimental Cardiovascular Medicine (A.C., E.P., N.K., A.O., M.M., B.C., P.M., C.E.), and Vascular Biology Divisions (G.B.S.-N.), Bristol Heart Institute, University of Bristol, UK; IRCCS Multimedica Hospital (E.P., G.S.), Milan, Italy; the Department of Molecular Cell Biology and Immunology (A.J.G.H.), VU University Medical Center Amsterdam, Netherlands; Pathology (G.G.), University of Parma, Italy; INSERM Cardiovascular Research Center (A.S.L., C.N.B.), Hôpital Lariboisière, Paris, France; and the Center for Molecular Neurobiology (S.O.Y.), Ohio State University, Columbus.

* To whom correspondence should be addressed. E-mail: Costanza.Emanueli{at}bristol.ac.uk.

Diabetes impairs endothelial function and reparative neovascularization. The p75 receptor of neurotrophins (p75NTR), which is scarcely present in healthy endothelial cells (ECs), becomes strongly expressed by capillary ECs after induction of peripheral ischemia in type-1 diabetic mice. Here, we show that gene transfer-induced p75NTR expression impairs the survival, proliferation, migration, and adhesion capacities of cultured ECs and endothelial progenitor cells (EPCs) and inhibits angiogenesis in vitro. Moreover, intramuscular p75NTR gene delivery impairs neovascularization and blood flow recovery in a mouse model of limb ischemia. These disturbed functions are associated with suppression of signaling mechanisms implicated in EC survival and angiogenesis. In fact, p75NTR depresses the VEGF-A/Akt/eNOS/NO pathway and additionally reduces the mRNA levels of ITGB1 [beta (1) integrin], BIRC5 (survivin), PTTG1 (securin) and VEZF1. Diabetic mice, which typically show impaired postischemic muscular neovascularization and blood perfusion recovery, have these defects corrected by intramuscular gene transfer of a dominant negative mutant form of p75NTR. Collectively, our data newly demonstrate the antiangiogenic action of p75NTR and open new avenues for the therapeutic use of p75NTR inhibition to combat diabetes-induced microvascular liabilities.


Key words: neurotrophins • p75NTR • VEGF-A • reparative neovascularization • limb ischemia